Retatrutide has moved from an early-stage peptide research candidate into a much broader clinical development program. During 2026, new Phase 3 results expanded the available research data across obesity, type 2 diabetes, cardiovascular disease, knee osteoarthritis, and other related areas. The research is attracting attention because retatrutide is designed as a triple hormone receptor agonist,[ Read more…]